Minute Insight: FDA Approves First Fluorescent Imaging Agent For Ovarian Cancer
On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
You may also be interested in...
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.
Results of the CLASP IID trial showed Edwards’ Pascal mitral valve repair system was non-inferior for safety and effectiveness compared to Abbott’s MitraClip device.